LDL is a surrogate endpoint used in clinical trials and evidence synthesis. RAGMD distinguishes hard outcomes from surrogate markers when weighing study directness.
LDL is a surrogate endpoint used in clinical trials and evidence synthesis. RAGMD distinguishes hard outcomes from surrogate markers when weighing study directness.